New Center Aims to Close Gap in Care for Postpartum Women

Obstetrician Louise Wilkins-Haug, MD, PhD, and endocrinologist Ellen Seely, MD, are leaders at the Brigham’s Center for Connected Postpartum Care. The pair discusses the need for this center, its multidisciplinary approach to care, and its early successes in managing hypertensive patients postpartum.

Read More...

Combination of SGLT2i, GLP-1 RA, and Non-Steroidal MRA Proposed for Patients With Type 2 Diabetes and Albuminuria

After analyzing data from pivotal trials, researchers at Brigham and Women’s Hospital believe treatment with a combination SGLT2i, GLP-1 RA, and nonsteroidal MRA has the potential to improve survival in patients with type 2 diabetes and at least moderately increased albuminuria.

Read More...

Study Shows Semaglutide Reduces Cardiovascular Events in People With Overweight or Obesity but Not Diabetes

The Brigham was part of a trial that shows for the first time that the weight loss drug semaglutide lowers the incidence of death from cardiovascular causes in those with overweight or obesity but not diabetes. Jorge Plutzky, MD, discusses the findings and implications for clinical care.

Read More...

New TIMI Risk Score Provides Individualized CV Risk Profile for Patients With Type 2 Diabetes

Using contemporary data sets reflecting current clinical practices, researchers at Brigham and Women’s Hospital developed the TIMI Risk Score for Atherothrombosis in Diabetes, which uses information readily available from the medical chart to predict atherothrombotic complications in patients with type 2 diabetes.

Read More...

Denosumab Use for Osteoporosis May Reduce Risk of Type 2 Diabetes

Close up of doctor holding syringe, denosumab medical injection concept

Clinical guidelines recommend denosumab for people with osteoporosis with a high fracture risk. Now, researchers at Brigham and Women’s Hospital have associated denosumab use with a 32% decreased risk of type 2 diabetes compared with the use of an oral bisphosphonate.

Read More...

Transoral Outlet Reduction Plus Pharmacotherapy Superior to Either Alone for Treating Weight Regain After RYGB

Brigham and Women’s Hospital researchers, and colleagues investigated the effect of combining pharmacotherapy with transoral outlet reduction. They demonstrate the combination is superior to either therapy alone and provides similar efficacy to surgical revision for weight gain after Roux-en-Y gastric bypass.

Read More...

Healthy Lifestyle Linked to Lower Risk of Microvascular Complications of Diabetes

Using two large prospective cohorts, Brigham and Women’s Hospital researchers have demonstrated that adherence to healthy practices both before and after a diabetes diagnosis is significantly associated with lower risk of microvascular complications.

Read More...

Peak Total and Free Testosterone in Women of Reproductive Age Are Higher Than Previously Reported

3D rendering of testosterone molecule, ball-and-stick molecular model

Measuring serum testosterone (T) levels in women aids in the diagnosis of disorders of androgen excess. Brigham and Women’s Hospital researchers examined changes in T and dihydrotestosterone levels, reporting higher levels of total and free T and emphasizing the need for menstrual phase–specific reference ranges.

Read More...

Safety and Tolerability of Semaglutide: Pooled Phase 3 Data

Close up of woman injecting insulin into stomach

Brigham and Women’s Hospital researchers report an integrated analysis of 18 randomized, controlled trials of semaglutide (17,639 patients), concluding its safety and tolerability are now well characterized—and similar for the subcutaneous and oral formulations.

Read More...

Hyperkalemia During Renin–Angiotensin–Aldosterone System Inhibitor Therapy Linked To Poorer Outcomes

A photograph of a tall peak T type cardiac electrodes that can tell if a patient has Hyperkalemia.

Hyperkalemia is one of the most common adverse reactions to renin–angiotensin–aldosterone system inhibitor (RAASi) therapy. In a recent study, Brigham and Women’s Hospital researchers found that patients who develop hyperkalemia while receiving RAASi therapy have a higher risk of poor outcomes.

Read More...